Literature DB >> 3359895

Adenocarcinoma of the anal ducts. A series of 21 cases.

S L Jensen1, M H Shokouh-Amiri, K Hagen, H Harling, O V Nielsen.   

Abstract

The records of 21 patients treated for adenocarcinoma of the anal ducts between 1943 and 1982 were reviewed. The patients were followed until death or current status in April 1987. The median follow-up period was eight months (range, 3 to 144 months). Fifteen patients had an erroneous diagnosis made at first physician visit resulting in a median doctor's delay of 14 months (range, 3 to 24 months) before correct treatment was carried out. Nine of the tumors were localized perianally (ischiorectal space), seven anally, and five in a fistula-in-ano. Tumors localized anally were significantly smaller and had a significantly shorter history than perianally or fistula-in-ano localized tumors (P less than .05 for each localization). Three patients with anal tumors had their diagnosis made accidentally by routine histologic examination of an excised hemorrhoid. First examination revealed distant metastases in 13 patients and follow-up examination revealed regional or distant metastases in seven patients. Modes of treatment were wide local excision (N = 3), abdominoperineal resection (N = 3), colostomy (N = 9), and radiotherapy (N = 2). Twenty of the 21 patients died within 18 months due to the cancer. One long-term survivor was observed; the patient was alive 12 years after local excision of the tumor without evidence of recurrent disease. The crude five- and 10-year survival was only 4.8 percent.

Entities:  

Mesh:

Year:  1988        PMID: 3359895     DOI: 10.1007/bf02554358

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  15 in total

1.  Carcinoma arising within an anal gland.

Authors:  M A Zeiton; B C Knight; Y N Khaled; R Green; N Mapstone; K Riyad
Journal:  BMJ Case Rep       Date:  2011-02-15

2.  Successful treatment of anal gland adenocarcinoma with combined modality therapy.

Authors:  Sean Warsch; Ulas Darda Bayraktar; B-Chen Wen; Joseph Zeitouni; Floriano Marchetti; Caio Max S Rocha-Lima; Alberto J Montero
Journal:  Gastrointest Cancer Res       Date:  2012-03

3.  Anal canal adenocarcinoma with MUC5AC expression suggestive of anal gland origin.

Authors:  Naoto Kuroda; Nobuyuki Tanida; Masahiko Ohara; Takashi Hirouchi; Keiko Mizuno; Ayumi Kubo; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2007-03-29       Impact factor: 2.309

4.  Synchronous rectal adenocarcinoma and anal canal adenocarcinoma.

Authors:  Jin Gu; Jiyou Li; Yunfeng Yao; Aiping Lu; Hongyi Wang
Journal:  Front Med China       Date:  2007-07-01

5.  Wide local excision of perianal mucinous adenocarcinoma.

Authors:  André M Ilbawi; Vlad V Simianu; Michael Millie; Perry Soriano
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

6.  Mucinous adenocarcinoma derived from chronic perianal fistulas: report of a case and review of the literature.

Authors:  R F Leal; M L S Ayrizono; C S R Coy; J J Fagundes; J R Góes
Journal:  Tech Coloproctol       Date:  2007-05-25       Impact factor: 3.781

7.  Successful treatment of rectal cancer with perineal invasion: Three case reports.

Authors:  Tomohiro Kitahara; Mamoru Uemura; Naotsugu Haraguchi; Junichi Nishimura; Tatsushi Shingai; Taishi Hata; Ichiro Takemasa; Tsunekazu Mizushima; Yuichiro Doki; Masaki Mori; Hirofumi Yamamoto
Journal:  Mol Clin Oncol       Date:  2014-04-17

Review 8.  Premalignant and Malignant Perianal Lesions.

Authors:  Mohammad Ali Abbass; Michael A Valente
Journal:  Clin Colon Rectal Surg       Date:  2019-08-22

9.  [Scrotal fistulas revealing mucinous adenocarcinoma of the scrotum: about a case].

Authors:  Abdelilah El Alaoui; Hicham El Boté; Oussama Ziouani; Oussman Dembele; Hachem El Sayegh; Ali Iken; Lounis Benslimane; Yassine Nouini
Journal:  Pan Afr Med J       Date:  2017-03-30

10.  A CARE-compliant article: a case report of primary adenocarcinoma of the anal glands: Review of literature.

Authors:  Yong Ji; Youxin Zhou
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.